Suchergebnisse - "Kazandjian, Dickran"

PubPharm (7)

1

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

enthalten in: Nature communications | 2022

von Yang, Y. | Bolomsky, A. | Oellerich, T. | +23

ErratumIn: Nat Commun. 2022 Oct 3;13(1):5830. - PMID 36192480

2

The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S

enthalten in: Seminars in oncology | 2022

von Peres, L. | Hansen, D. | Maura, F. | +1

3

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma : A Phase 2 Nonrandomized Controlled Trial

enthalten in: JAMA oncology | 2021

von Kazandjian, D. | Hill, E. | Dew, A. | +31

4

Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models

enthalten in: JAMA oncology | 2021

von Hill, E. | Dew, A. | Morrison, C. | +4

5

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

enthalten in: Scientific reports | 2019

von Huang, P. | Beedie, S. | Chau, C. | +7

6

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

enthalten in: Bone marrow transplantation | 2018

von Tageja, N. | Korde, N. | Kazandjian, D. | +10

7

Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma

enthalten in: Cancer research | 2013

von Akagi, I. | Okayama, H. | Schetter, A. | +16

1
[1]